Skip to main content
SpringerLink
Log in

Omalizumab als therapeutische Alternative beim atopischen Ekzem

Bisherige Evidenz und potenzieller Nutzen

Omalizumab as a therapeutic option in atopic eczema

Current evidence and potential benefit

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Der monoklonale Anti-IgE-Antikörper Omalizumab ist derzeit zur Behandlung des schweren allergischen Asthmas zugelassen. Randomisierte klinische Studien bei der Indikation „atopisches Ekzem“ liegen bisher nicht vor. Der Beitrag gibt einen Überblick über die derzeitige Datenlage zur Wirksamkeit von Omalizumab beim atopischen Ekzem. Mittels einer systematischen Literaturrecherche wurden 3 Fallserien identifiziert. Diese legen nahe, dass möglicherweise die Subgruppe der Patienten mit extrinsischem atopischem Ekzem und moderat hohen IgE-Werten von einer Omalizumab-Therapie profitiert. Die Durchführung einer randomisierten klinischen Studie ist wichtig, um den Stellenwert von Omalizumab beim atopischen Ekzem systematisch zu untersuchen. Darüber hinaus würde eine solche Studie zur Klärung der pathogenetischen Bedeutung von IgE beim atopischen Ekzem beitragen.

Abstract

The monoclonal anti-IgE antibody omalizumab is currently approved for the treatment of severe asthma. Randomized controlled trials for the indication atopic eczema have not yet been performed. This paper summarizes the current evidence on the effectiveness of omalizumab in atopic eczema. Using a systematic electronic search strategy, we identified three case series. These suggest that a subgroup of patients with extrinsic atopic eczema but only moderately elevated IgE levels might benefit most from omalizumab treatment. A randomized controlled trial should be performed to clarify the potential benefit of omalizumab for patients with atopic eczema. Additionally, such a study might help us to better understand the role of IgE in the pathogenesis of atopic eczema.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Adelroth E, Rak S, Haahtela T et al. (2000) Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106: 253–259

    Article  PubMed  Google Scholar 

  2. Beck LA, Saini S (2006) Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 55: 540–541

    Article  PubMed  Google Scholar 

  3. Casale TB, Condemi J, LaForce C et al. (2001) Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286: 2956–2967

    Article  PubMed  Google Scholar 

  4. Chang TW (2006) Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E. Allergy Asthma Proc 27: 7–14

    Google Scholar 

  5. Holgate S, Casale T, Wenzel S et al. (2005) The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115: 459–465

    Article  PubMed  Google Scholar 

  6. Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53: 338–340

    Article  PubMed  Google Scholar 

  7. Lane JE, Cheyney JM, Lane TN et al. (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54: 68–72

    Article  PubMed  Google Scholar 

  8. Lanier B (2006) Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc 27: 37–42

    Google Scholar 

  9. Leynadier F, Doudou O, Gaouar H et al. (2004) Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 113: 360–361

    Article  PubMed  Google Scholar 

  10. Lin H, Boesel KM, Griffith DT et al. (2004) Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113: 297–302

    Article  PubMed  Google Scholar 

  11. Maurer D, Fiebiger S, Ebner C et al. (1996) Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol 157: 607–616

    PubMed  Google Scholar 

  12. Milgrom H, Fick RB Jr, Su JQ et al. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341: 1966–1973

    Article  PubMed  Google Scholar 

  13. Reich K, Heine A, Hugo S et al. (2001) Engagement of the Fc epsilon RI stimulates the production of IL-16 in Langerhans cell-like dendritic cells. J Immunol 167: 6321–6329

    PubMed  Google Scholar 

  14. Schmitt J, Schäkel K, Schmitt NM, Meurer M (2007) Systemic treatment of severe atopic eczema – a systematic review. Acta Derm Venereol 87 (in press)

  15. Vigo PG, Girgis KR, Pfuetze BL et al. (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55: 168–170

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland

    J. Schmitt MPH & K. Schäkel

Authors
  1. J. Schmitt MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Schäkel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Schmitt MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmitt, J., Schäkel, K. Omalizumab als therapeutische Alternative beim atopischen Ekzem. Hautarzt 58, 128–132 (2007). https://doi.org/10.1007/s00105-006-1280-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-006-1280-y

Schlüsselwörter

Keywords

Search

Navigation